Allergy Therapeutics

Next week, our CEO, Manuel LLobet, will be participating in a #panel discussion at the Financial Times’ ‘Scaling Competitive Biopharma in Europe’ event. Held on 3 June in London, UK, and virtually, this event will focus on the key factors contributing to #commercial launch success and explore how to scale the next generation of globally competitive #biopharma companies. During the panel discussion, ‘Optimising product launch and commercialisation: building resilience in a volatile market’, Manuel will share his perspective on launch strategies and navigating uncertainty both pre- and post-approval, drawing on his experiences leading an international business with a broad commercial presence across Europe and a differentiated pipeline of #allergy immunotherapies. Register here to view the event agenda and secure your place: https://lnkd.in/ev95Qk-m #Leadership #Conference #Immunotherapy #Biotech

#FoodAllergies are often thought of as occasional or manageable conditions, but the data tells a very different story.   In the United States alone, around 33 million people are living with potentially life-threatening food allergies. For some, the risk is immediate and unpredictable, with emergency departments treating a food allergy reaction every 10 seconds.   Even more striking, estimates suggest that 1 in 3 children may be affected by life-threatening food allergies, highlighting just how early and widespread this condition has become.   Behind each of these figures is a person navigating daily uncertainty, reading labels carefully, constantly planning, and managing the risk of accidental exposure in everyday environments.   #FoodAllergy #AllergyAwareness #PublicHealth #Biotech #Innovation #FoodAllergyAwarenessWeek

Peanut allergy remains one of the most common food allergies, placing a significant daily burden on those affected and their families. Despite this, treatment options remain limited.   At Allergy Therapeutics, we believe that transformational outcomes for patients are achieved by directly treating the cause of #allergy, rather than just managing symptoms, and today, as part of #FoodAllergyAwarenessWeek, we’re spotlighting our work to advance new therapeutic approaches for patients living with #PeanutAllergy.   Our #pipeline includes the development of an innovative short-course peanut allergy vaccine candidate, VLP Peanut, which is designed to target the underlying immune response to peanut allergens.   With plans underway to prepare VLP Peanut for a Phase IIb trial, we are thankful to the scientists, clinicians and those living with allergies who help us to progress this vital #research.   #FoodAllergy #Innovation #Biotech #AllergyAlly #PeanutAllergy #Allergy

Sunday marked the start of Food Allergy Awareness Week, an annual campaign by Food Allergy Research and Education (FARE) to raise awareness and inspire change for the millions of people living with #FoodAllergies.   Education and advocacy remain some of the most important ways we can challenge common misconceptions and equip people with accurate, evidence-based information about food allergies. By improving awareness and understanding, we can help create safer, more supportive environments for those affected.   To learn more about #FoodAllergyAwarenessWeek, visit: https://lnkd.in/enEF2W-C.      #PeanutAllergy #Biotech #Immunotherapy #Allergy #FoodAllergyAwarenessWeek

This week marks #AllergyAwarenessWeek in the UK, a timely reminder of the importance of shining a light on this often-underestimated health challenge.   While allergies affect millions of people, Allergy UK highlights that many will live with symptoms for years without understanding what is causing their #allergy or how to manage it. This year’s theme, “I Wish I Knew… Diagnosis Matters”, highlights the importance of recognising the signs and symptoms of allergy, seeking the right diagnosis and improving awareness of the available treatments and support to patients and their families.   At Allergy Therapeutics, we’re committed to making a long-term difference to people living with allergy through carefully designed clinical programmes in areas of significant patient need and by breaking new ground in #immunology research.     Learn more here:  https://lnkd.in/eqdKW-n7 #Biotech #Healthcare #Innovation #FoodAllergy #GrassAllergy #DiagnosisMatters #itsTimeToTakeAllergySeriously

Today we announced our interim results for the six months ended 31 December 2025. With significant commercial and clinical progress, bolstered by the successful marketing authorisation in Germany for our subcutaneous #GrassPollen allergy #immunotherapy, Allergy Therapeutics enters the second half of FY2026 with strong momentum across all aspects of the business.   Key highlights include: • Revenue growth of 7% to £36.3 million and a substantially strengthened balance sheet • Launch of our subcutaneous grass pollen allergy immunotherapy in Germany, with strong response seen from prescribing clinicians  • Progression of our G308 Phase III paediatric study of Grass MATA MPL to its planned second year of recruitment • Achievement of primary safety endpoint in Phase I/IIa #ClinicalTrial with VLP Peanut, our short-course #PeanutAllergy vaccine candidate  • Continued exploration of potential dual primary listing on Hong Kong Stock Exchange Read the full press release here: https://lnkd.in/eqPMD32T #Allergy #Biotech #Healthcare #Investors #Innovation #FoodAllergy #GrassAllergy #FinancialResults

Following achievement of the primary safety endpoint at the highest planned treatment dose, today we shared biomarker results from the Phase II/IIa PROTECT #ClinicalTrial trial of VLP Peanut, our innovative, short-course #PeanutAllergy drug candidate.   The comprehensive panel of efficacy #biomarkers demonstrated a strong immunomodulating response compared to placebo, which was consistent in all peanut allergic patients after treatment with VLP Peanut. Supported by previously shared supportive safety and tolerability data, PROTECT is currently progressing to deliver longer-term biomarker and scheduled safety assessments, and preparations are ongoing for a Phase IIb study.   To learn more, read the full press release here: https://lnkd.in/eA2RxyAZ   #FoodAllergy #Innovation #Biotech #DrugDevelopment #Immunotherapy #Immunology

We will be sharing key scientific findings at the 2026 American Academy of Allergy, Asthma & Immunology - AAAAI Annual Meeting, taking place in Philadelphia from tomorrow, 27 February, to 2 March. Our three poster presentations, which include supportive clinical and biomarker data from the ongoing G308 Phase III long-term paediatric study investigating Grass MATA MPL and the Phase I/IIa PROTECT trial of VLP Peanut, will showcase data from across our #pipeline and reflect the breadth and momentum of our clinical portfolio.   We look forward to hearing about the latest research and clinical updates from fellow industry professionals, clinicians and friends. For more information, read the full press releases here https://lnkd.in/eJVCKfjH #allergy #biotech #immunotherapy #grassAllergy #foodAllergy #allergyResearch #peanutAllergy

We are excited to announce the recent #appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director and Lawrence Wang as Independent Non-Executive Director.   Helge joins Allergy Therapeutics with over 30 years of experience leading global investment banks in the US and Asia, most recently serving as Vice Chairman, Global Banking at HSBC Holdings. In his newly created role as Chief Strategy Officer, he will drive our long-term #growth strategy as we advance our next-generation #pipeline and explore opportunities to deliver on our global ambitions. Lawrence brings more than two decades of #healthcare and investment experience and currently serves as Chief Financial Officer at Adicon Clinical Laboratories, one of China’s leading independent clinical laboratory service providers.  Lawrence will bring deep insights into Asian market opportunities for Allergy, drawing on his experience of leading Adicon through a successful Hong Kong Stock Exchange listing. Welcome to the team, Helge and Lawrence! Read the full press release here: https://lnkd.in/eefPE26k #Allergy #Biotech #Leadership #Healthcare #Investors #Innovation #FoodAllergy #GrassAllergy #Immunotherapy #Appointment

In collaboration with the European Academy of Allergy and Clinical Immunology - EAACI and Bencard Allergie GmbH, Allergy Therapeutics is excited to once again be sponsoring the EAACI Early Career Research Award!   Supporting the next generation of researchers is essential to advancing our understanding of #allergy and #immunology, and this distinguished award provides early-career #researchers and #clinicians with recognition on the international stage. It offers up to €30,000 in unrestricted research funding for pioneering allergy and immunology projects, with the winner being honoured at the EAACI Congress 2026 Opening Ceremony in Istanbul, Turkey. Please use the link below to apply before Saturday, 31 January 2026. #allergy #biotech #immunotherapy #grassAllergy #foodAllergy #award #EAACI #researchAward #allergyResearch